Crispr Theraptc (NASDAQ:CRSP) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 998,670 shares, an increase of 60.7% from the October 13th total of 621,347 shares. Approximately 8.7% of the company’s stock are sold short. Based on an average daily trading volume, of 210,975 shares, the short-interest ratio is presently 4.7 days.

Crispr Theraptc (NASDAQ CRSP) opened at $17.45 on Monday. Crispr Theraptc has a 1-year low of $11.63 and a 1-year high of $25.00.

Crispr Theraptc (NASDAQ:CRSP) last posted its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Crispr Theraptc had a negative net margin of 466.58% and a negative return on equity of 38.42%. The company had revenue of $2.39 million for the quarter, compared to the consensus estimate of $3.61 million. During the same quarter last year, the business earned ($2.77) earnings per share. Crispr Theraptc’s quarterly revenue was up 54.2% on a year-over-year basis. equities analysts expect that Crispr Theraptc will post -2.49 EPS for the current year.

In other news, Director Kurt Von Emster sold 55,569 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $19.59, for a total value of $1,088,596.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Samarth Kulkarni sold 27,154 shares of the firm’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $20.08, for a total value of $545,252.32. Following the completion of the sale, the insider now directly owns 110,893 shares of the company’s stock, valued at approximately $2,226,731.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 343,060 shares of company stock valued at $6,778,681. 39.98% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN raised its holdings in Crispr Theraptc by 129.8% during the third quarter. Wells Fargo & Company MN now owns 18,352 shares of the company’s stock valued at $328,000 after buying an additional 10,365 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Crispr Theraptc during the third quarter valued at about $536,000. Bank of New York Mellon Corp bought a new position in shares of Crispr Theraptc in the third quarter worth about $288,000. New York State Common Retirement Fund bought a new position in shares of Crispr Theraptc in the third quarter worth about $344,000. Finally, Capital Investment Advisory Services LLC bought a new position in shares of Crispr Theraptc in the third quarter worth about $193,000. Institutional investors own 25.52% of the company’s stock.

CRSP has been the subject of several recent research reports. Chardan Capital reiterated a “buy” rating on shares of Crispr Theraptc in a report on Monday, August 14th. Barclays PLC reiterated a “buy” rating and set a $29.00 price objective on shares of Crispr Theraptc in a report on Friday, September 8th. Cann reiterated a “hold” rating on shares of Crispr Theraptc in a report on Thursday. SunTrust Banks, Inc. reiterated a “hold” rating and set a $16.00 price objective on shares of Crispr Theraptc in a report on Friday. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $23.08.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/crispr-theraptc-crsp-sees-large-increase-in-short-interest-2/1699015.html.

Crispr Theraptc Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with Analyst Ratings Network's FREE daily email newsletter.